Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Ravoxertinib

Catalog No: tcsc3704

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:
1453848-26-4

Formula:
$C_{21}H_{18}ClFN_6O_2$

Pathway:
Stem Cell/Wnt;MAPK/ERK Pathway

Target:
ERK;ERK

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 35 mg/mL (79.39 mM)

Alternative Names:
GDC-0994

Observed Molecular Weight:
440.86

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Ravoxertinib (GDC-0994) is an orally bioavailable **ERK** kinase inhibitor with an **IC_{50}** of 6.1 nM and 3.1 nM for **ERK1** and **ERK2**, respectively.

IC50 & Target: IC50: 6.1 nM (ERK1), 3.1 nM (ERK2), 12 nM (p90RSK)[1]

In Vitro: Ravoxertinib (GDC-0994) also inhibits p90RSK with IC_{50} of 12 nM[1]. Ravoxertinib (GDC-0994) is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively[2].

In Vivo: In CD-1 mice, a 10 mg/kg oral dose of Ravoxertinib (GDC-0994) is sufficient to achieve the desired target coverage for at least 8 h[1]. Daily, oral dosing of Ravoxertinib results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice[2].